All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
On May 4, 2022, it was announced that the European Commission (EC) had approved the use of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who previously received ≥2 lines of systemic therapy. This is the third indication tisagenlecleucel has been approved for in the EU and the first CAR T-cell therapy approved for the treatment of FL, including patients with Grade 1, 2, and 3A relapsed or refractory FL.1 The approval is based on key data obtained from the phase II ELARA trial (NCT03568461), previously reported on the Lymphoma Hub.
Of the 97 heavily pretreated patients who received tisagenlecleucel, 94 were evaluable for efficacy and 97 were evaluable for safety. The median follow-up time was approximately 21 months.
Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint
On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating tisagenlecleucel in patients with relapsed or...
The FDA grants regenerative medicine advanced therapy (RMAT) designation to tisagenlecleucel for patients with relapsed or refractory follicular lymphoma
Tisagenlecleucel has been granted regenerative medicine advanced therapy (RMAT) designation by...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox